Stryker price target raised to $310 from $280 at Piper Sandler

Piper Sandler analyst Matt O’Brien raised the firm’s price target on Stryker to $310 from $280 and keeps an Overweight rating on the shares. The upside in Q1 was broad-based as the company continues to capitalize on strong volume trends and new product introductions. the analyst tells investors in a research note. The firm believes the momentum across the business is "very strong, which should be buoyed by the super cycle."